TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04709003

Intervention type: DIAGNOSTIC_TEST
Intervention: Serologic test
Description: A blood test to check antibodies type and amount

Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory swabs
Description: PCR test to Covid-19

Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory swabs
Description: PCR test to Covid-19
Study: NCT04145076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two oral doses of placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two oral doses of placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two oral doses of placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two oral doses of placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two oral doses of placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Two oral doses of placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Single oral dose of citalopram (20mg) and single oral dose of placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Single oral dose of citalopram (20mg) and single oral dose of placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Single oral dose of citalopram (20mg) and single oral dose of placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Single oral dose of citalopram (20mg) and single oral dose of placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Single oral dose of citalopram (20mg) and single oral dose of placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Single oral dose of citalopram (20mg) and single oral dose of placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tianeptine
Description: Single oral dose of tianeptine (12.5mg) and single oral dose of placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tianeptine
Description: Single oral dose of tianeptine (12.5mg) and single oral dose of placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tianeptine
Description: Single oral dose of tianeptine (12.5mg) and single oral dose of placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tianeptine
Description: Single oral dose of tianeptine (12.5mg) and single oral dose of placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tianeptine
Description: Single oral dose of tianeptine (12.5mg) and single oral dose of placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tianeptine
Description: Single oral dose of tianeptine (12.5mg) and single oral dose of placebo.
Study: NCT06268002

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sweetener
Study: NCT01962896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Study: NCT03781869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride; etoposide and cisplatin
Description: etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1 and Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle, repeated every 21 days
Study: NCT02452073

Intervention type: OTHER
Intervention: Thyroid function tests

Intervention type: OTHER
Intervention: Thyroid function tests

Intervention type: OTHER
Intervention: Thyroid function tests
Study: NCT02586142

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by ultrasounds guidance.
Study: NCT03848572

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Repetitive assessment of PRECISE-DAPT score
Description: The PRECISE-DAPT score, which takes into consideration age, creatinine clearance, haemoglobin, white blood-cell count and previous spontaneous bleeding, will be reassessed every 3 months during the 12-month follow-up period
Study: NCT03014375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA-5-453
Description: Each subject will receive a single oral dose of 100 μCi/ 3.7 MBq 14C labeled BIA 5-453 (600 mg).
Study: NCT03224858

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SUMMIT intervention
Description: See description in experimental arm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: See description in active comparator arm.
Study: NCT04498234

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided erector spinae plane block with bupivacaine 0.25% And ultrasound guided Paraveretebral block with bupivacaine 0.25 %
Description: One groupvwill receive 0.25% bupivacaine (20 ml ) into interfascial plane below erector spinae muscle at level of T4 and the other group willreceive (0.3 ml /kg ) 0.25% bubivicaine divided equially at each level of T2 , T4 and T6 at thoracic paravertebral space .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided erector spinae plane block with bupivacaine 0.25% And ultrasound guided Paraveretebral block with bupivacaine 0.25 %
Description: One groupvwill receive 0.25% bupivacaine (20 ml ) into interfascial plane below erector spinae muscle at level of T4 and the other group willreceive (0.3 ml /kg ) 0.25% bubivicaine divided equially at each level of T2 , T4 and T6 at thoracic paravertebral space .
Study: NCT02586142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by ultrasounds guidance.
Study: NCT01072721

Intervention type: OTHER
Group type: OTHER
Intervention: Elastometry
Description: Fibrosis detection with FIBROSCANN
Study: NCT00420381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 mg loading dose then 500 mg, oral, daily, until progressive disease
Study: NCT00618007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00734200 30 mg QD
Description: 30 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00734200 20 mg QD
Description: 20 mg QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01516632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS USA
Description: Intervention participants receive text messages daily pre-and post-quit. Everyone receives messages 14 days prior to the Quit day, and through the day after Quit. Then, participants are 'pathed' to particular messages based upon their self-reported smoking status at Day 2 and Day 7 post quit, respectively. Those who are successful at quitting receive messages aimed at relapse prevention whereas those who have slipped receive messages aimed at getting the person to recommit to quitting and trying again.
Study: NCT02479880

Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir DF
Description: 300 mg tablet administered orally once daily for up to 96 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Tenofovir DF
Description: 300 mg tablet administered orally once daily for up to 96 weeks

Intervention type: RADIATION
Group type: OTHER
Intervention: DEXA Scan
Description: Dual energy x-ray absorptiometry (DEXA) scans administered at protocol-specified time points
Study: NCT02586142

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercise
Description: After accepting Botulinum toxin type A injection, participants will be arranged to receive stretch exercise in Kaohsiung Chang Gung Memorial Hospital 3 times per week, for 3 month.
Study: NCT02479880

Intervention type: RADIATION
Group type: OTHER
Intervention: DEXA Scan
Description: Dual energy x-ray absorptiometry (DEXA) scans administered at protocol-specified time points
Study: NCT02431546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Health Application
Description: Health coaching is an innovative, holistic approach oriented towards one's full health and wellbeing. Coaches provide mentoring and support regarding many areas of life that impact one's health with a focus on skill-building. Health coaches do not provide medical advice, treat any medical conditions, provide mental health therapy, or provide individualized assessments of nutrient needs. Health coaches will not conduct medication counseling activities that would alter the prescribed regimen nor provide medication information/advice that would be considered the practice of medicine or pharmacy.~A Fitbit activity monitor will be used to track daily physical activity and provide real-time feedback to the participant.
Study: NCT00355368

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Succinylcholine
Description: 1mg/kg iv

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: 0.6mg/kg iv
Study: NCT01436110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 50mcg
Description: Once daily inhalation powder via Novel Dry Powder Inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate 100mcg
Description: Twice daily inhalation powder via DISKUS/ACCUHALER

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation powder via Novel Dry Powder Inhaler and DISKUS?ACCUHALER
Study: NCT01141127

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Comparison of two dosage regimen of Tranexamic Acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Comparison of two dosage regimen of Tranexamic Acid
Study: NCT03781869

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: etoposide and cisplatin
Description: etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1, repeated every 21 days
Study: NCT04013204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endothelial function guided therapy
Description: To evaluate the effect of integration of non invasive endothelial function test (EFT) as a routine test in increasing appropriate treatment to reduce cardiovascular risk including prescription of lipid, blood pressure and glucose lowering medications by physicians at the clinic for patients with non-obstructive coronary artery disease (NOCAD) and the effect of introducing EFT as a routine test in reducing clinical endpoint (major adverse cardiovascular events) among patients with non-obstructive coronary artery disease(NOCAD).
Study: NCT00833794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03072992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: Curcumin (CUC-01), 300mg i.v. , once weekly for 12 weeks.
Study: NCT03039738

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vital Sync IM & VPMP (Surveillance Monitoring)
Description: The Vital Sync™ Informatics Manager (IM) \& Virtual Patient Monitoring Platform (VPMP) is an electronic medical record connectivity and remote continuous patient monitoring software solution.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telemetry Monitoring
Description: Continuous ECG monitoring for hospitalized patients at-risk for cardiac events.
Study: NCT03713879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pancreatic stenting
Description: a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025 or .035 wire)
Study: NCT03287869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Brexpiprazole tablets
Study: NCT00647257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Losartan 100mg add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
Study: NCT03713879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pancreatic stenting
Description: a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025 or .035 wire)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: rectally administered indomethacin before or after ERCP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: rectally administered indomethacin before or after ERCP
Study: NCT04162132

Intervention type: DEVICE
Intervention: Smartphone app
Description: Study procedures related to the DynamiCare Rewards intervention were conducted via smartphone. Research visits included collection of urine samples and medical exams. Participants assigned to the DynamiCare Rewards group received: 1) the app on their smartphone, 2) drug testing devices when indicated (pocket-sized breathalyzer), and a reloadable debit card for receiving the financial incentives (the PEX debit card). Global Positioning System (GPS) tracking was used to track whether patients had attended their scheduled appointments but was not used at any other times. All information was uploaded from the app onto the DynamiCare Analytics website, which treatment providers could view. The information reported was: attendance status of appointments, the status of all alcohol and drug testing, and incentives earned. Each patient's intervention period (period of time when they used the app) lasted four months from the date of their enrollment.
Study: NCT03453671

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Participants will use mindfulness techniques while exercising

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction
Description: Participants will distract themselves while exercising

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring
Description: Participants will use associative attentional focus while exercising
Study: NCT00647257

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Placebo add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
Study: NCT00415519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-186
Description: Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of MCI-186
Description: Two ampoules of Placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
Study: NCT03327519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHUTi
Description: Sleep Healthy Using the Internet (SHUTi) is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of CBT-I: sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emmi
Description: The Emmi® program for insomnia contains educational information on physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors (e.g., reduce time in bed, get up at the same time every day, go to bed only if sleepy, and do not stay in bed unless asleep), and sleep medications; assesses self-efficacy, and; allows patients to set individual goals.
Study: NCT03958539

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D printed insoles for normal footware
Description: Imprints are low-cost, bespoke, 3D-printed orthotics designed to prevent diabetic foot ulceration by redistributing and lowering peak foot pressures. This is achieved by using different density zones designed specifically for the patient. The patient's foot shape and pressure zone are capture by a 3D imaging system. Once scanned the software automatically identifies the peak pressure zones, matches these with the correct material and stiffness (densities), fits the insole arch to the patient and generates the insole.~The imprints insole is divided into four pressure zones: heel, midfoot, metatarsal head region and toes. These zones are printed with different stiffness to account for the difference in loading between them. The design of the pressure zones is automatically matched to the shape of each individual foot with the help of the 3D scan.
Study: NCT04087603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekend Morning Bright Light & Early Bedtime
Study: NCT02398084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing of nuts
Description: The volunteers will be asked to chew and spit 8 portions (4-5 g) of nuts (cashews or walnuts) on two separate visits. They will provide samples for particle sizing. Two portions will be used as practice samples in order to measure the number of chews. Two portions will be sieved. Two portions will be measured by laser diffraction. Two portions will be frozen for later lipid analysis.
Study: NCT03255265

Intervention type: OTHER
Intervention: no interventions
Description: no interventions

Intervention type: OTHER
Intervention: no interventions
Description: no interventions
Study: NCT00613717

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folic acid + iron prenatally, vits A & D + iron postnatally
Description: Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1 mg/kg/day Fe, 1500 IU vitamin A, 500 IU vitamin D.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folic acid + iron prenatally, vitamins A & D postnatally
Description: Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1500 IU vitamin A, 500 IU vitamin D.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folic acid prenatally, vitamins A & D + iron postnatally
Description: Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1 mg/kg/day Fe, 1500 IU vitamin A, 500 IU vitamin D.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: folic acid prenatally, vitamins A & D postnatally
Description: Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1500 IU vitamin A, 500 IU vitamin D.
Study: NCT01899586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regional Specific Training Stimulus (RSTS)
Description: The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Regimen (AE)
Description: Whole-body aerobic exercise at \>50% of heart rate reserve (HRR) for 45 minutes, three days per week.
Study: NCT02271009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AllerT
Description: Ultrafast immunotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AllerT
Description: Ultrafast immunotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AllerT
Description: Ultrafast immunotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo control
Study: NCT03072992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel (colorless solution) 80 mg /m2 BS, i.v., once weekly for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel (colorless solution) 80 mg /m2 BS, i.v., once weekly for 12 weeks.
Study: NCT04101578

Intervention type: DRUG
Intervention: Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg)
Description: Treatment regimens are determined according to the physician's judgment and preferences of the patients.

Intervention type: DRUG
Intervention: Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg)
Description: Treatment regimens are determined according to the physician's judgment and preferences of the patients.
Study: NCT02427750

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aggripal®
Description: TIV
Study: NCT00648661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram Oxalate Tablets 20 mg
Description: 20mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lexapro® Tablets 20 mg
Description: 20mg, single dose fed
Study: NCT00469157

Intervention type: DRUG
Group type: OTHER
Intervention: Optive
Description: Optive 30ml- (in the eye) Instill one in each eye twice daily starting one week after surgery
Study: NCT05038579

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Musiquence
Description: The participants performed a customized cognitive stimulation program, that was implemented in an augmented reality format, using Musiquence.
Study: NCT00392236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-way pager
Description: Participants will receive messages daily to take their medication via a 2-way pager for 6 months. Once the message is received the participant will respond whether or not he/she took the medication and reason for not taking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Participants will receive treatment as usual.